Bacteremia
Recent clinical, regulatory, research and industry developments relating to this disease.
Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
- Q2 2027Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- Q4 2028Staphylococcus Aureus Network Adaptive Platform Trial
- Q1 2030Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Clinical MilestonesViewHide
- 2026-07-17DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus BacteremiaResults expected Q1 2027
- 2026-05-06Staphylococcus Aureus Network Adaptive Platform TrialResults expected Q4 2028
- 2026-03-20Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus BacteremiaResults expected Q1 2030
- 2026-03-11Gram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialResults expected Q2 2027
- 2026-07-01Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)Primary completion
- 2025-09-23Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus AureusPrimary completion
- 2026-07-17ClinicalDAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus BacteremiaResults expected Q1 2027
- 2026-07-01ClinicalCefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)Primary completion
- 2026-05-06ClinicalStaphylococcus Aureus Network Adaptive Platform TrialResults expected Q4 2028
- 2026-03-20ClinicalDabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus BacteremiaResults expected Q1 2030
- 2026-03-11ClinicalGram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialResults expected Q2 2027
- 2025-09-23ClinicalRandomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus AureusPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Bacteremia2
- Methicillin-Resistant Staphylococcus aureus2
- Brain Abscess1
- Cephalosporin Resistance1
- Communicable Diseases1
- Empyema, Pleural1
- Endocarditis1
- Foodborne Diseases1
Leading journals6
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America3
- The New England journal of medicine2
- Circulation1
- Epidemiology and infection1
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin1
- PLoS medicine1
Leading researchers8
- Fowler VG Jr2
- Abrutyn E1
- Adegboye O1
- Baddour LM1
- Baltimore RS1
- Barsic B1
- Bayer AS1
- Becker K1
Affiliations (unnormalised)6
- Akershus University Hospital1
- Australian Institute of Tropical Health and Medicine1
- Cantonal Hospital of Sion and Institut Central des Hôpitaux1
- Centre for Infectious Disease Control1
- College of Public Health1
- Department of Clinical Science1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Bacteremia is the presence of viable bacteria circulating in the blood. It commonly presents with acute systemic features such as fever, chills, tachycardia, and tachypnea. The condition is often seen in hospitalized patients, particularly those with underlying diseases or procedures that make the bloodstream more susceptible to invasion.
The grounding supports bacterial invasion of the bloodstream as the immediate cause of bacteremia, but does not provide a more specific aetiology. It also indicates that many cases occur in hospitalized patients with underlying conditions or procedures that predispose to bloodstream invasion. Specific causative organisms are not established in the supplied definition, although bloodstream infections are discussed in relation to pathogens such as Staphylococcus aureus and several food-borne bacterial species.
The core biological event is the circulation of viable bacteria in the blood. The supplied material also links bacteremia to systemic acute manifestations including fever, chills, tachycardia, and tachypnea, consistent with a host inflammatory response to bloodstream infection. In the reviewed literature, bacteremia is also discussed as a bloodstream infection state associated with specific pathogens and healthcare-associated infection contexts.
Hospitalization is a major context in which bacteremia occurs. Underlying diseases and procedures that render the bloodstream susceptible to invasion increase risk. The supplied abstracts also point to healthcare-associated factors and, for some pathogens, community or livestock-associated exposure contexts, but do not define bacteremia-specific risk factors beyond susceptibility to bloodstream invasion.
The supplied grounding does not describe a general treatment standard for bacteremia. It only indicates that the literature covers diagnosis and microbiology, and that bacteremia is discussed in the context of antimicrobial therapy for related bloodstream infections such as infective endocarditis. No specific modality or drug-class standard of care is supported here.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.